DFTX:NASDAQ
Definium Therapeutics Inc
$38.09
arrow_upward
+0.24%(+0.090) 1D
$37.91
arrow_downward
-0.47% (-0.18)bedtimeAfter hours
Closed: Sep 4, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DFTX...
Open
$37.94
High
$38.54
Low
$37.38
Mkt. cap
5.12B
Avg. vol.
2.05M
Volume
1.13M
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
Open
$37.94
High
$38.54
Low
$37.38
Mkt. cap
5.12B
Avg. vol.
2.05M
Volume
1.13M
52-wk high
$49.70
52-wk low
$14.62
EPS
-$3.43
Beta
2.23
Shares outstanding
134.37M
No. of employees
106
News stories
From web sources and news partners
Investing.com
·
2 hours ago
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares
Quiver Quantitative
·
14 hours ago
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress
Stock Titan
·
1 day ago
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorPharmaceutical industry
Websitedefiniumtx.com